» Articles » PMID: 26161701

Rapid Detection of Urinary Long Non-coding RNA Urothelial Carcinoma Associated One Using a PCR-free Nanoparticle-based Assay

Overview
Journal Biomarkers
Specialty Biochemistry
Date 2015 Jul 11
PMID 26161701
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

We developed a specific hybridization assay for direct detection of long non-coding RNA urothelial carcinoma associated-1 (lncRNA-UCA1). Total RNA was extracted from urine pellet samples (bladder carcinoma patients and controls). Then, we compared the developed nanoassay with quantitative real time polymerase chain reaction (qRT-PCR) results in detection of urine UCA1 in bladder cancer and control samples. The sensitivity and the specificity of UCA1 nanoassay were 92.1% and 93.3%, respectively. The concordance of the two methods was 98%. Interestingly, all bilharzial benign cases showed negative lncRNA-UCA1 using both methods. UCA1-nanoassay is a valid test for direct detection of urine UCA1 for bladder cancer detection.

Citing Articles

Diagnosis and management of complicated urogenital schistosomiasis: a systematic review of the literature.

Manciulli T, Marangoni D, Salas-Coronas J, Bocanegra C, Richter J, Gobbi F Infection. 2023; 51(5):1185-1221.

PMID: 37466786 PMC: 10545601. DOI: 10.1007/s15010-023-02060-5.


Urine biomarkers in bladder cancer - current status and future perspectives.

Maas M, Todenhofer T, Black P Nat Rev Urol. 2023; 20(10):597-614.

PMID: 37225864 DOI: 10.1038/s41585-023-00773-8.


Nanomedicine for Combination Urologic Cancer Immunotherapy.

Tian Y, Liu Z, Wang J, Li L, Wang F, Zhu Z Pharmaceutics. 2023; 15(2).

PMID: 36839868 PMC: 9960671. DOI: 10.3390/pharmaceutics15020546.


Radio-lncRNAs: Biological Function and Potential Use as Biomarkers for Personalized Oncology.

Kozlowska-Maslon J, Guglas K, Paszkowska A, Kolenda T, Podralska M, Teresiak A J Pers Med. 2022; 12(10).

PMID: 36294743 PMC: 9604926. DOI: 10.3390/jpm12101605.


Exosomal lncRNAs: the newest promising liquid biopsy.

Tellez-Gabriel M, Heymann D Cancer Drug Resist. 2022; 2(4):1002-1017.

PMID: 35582278 PMC: 9019197. DOI: 10.20517/cdr.2019.69.